Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a topical gel formulation containing a combination of two active ingredients: adapalene (0.3%) and benzoyl peroxide (2.5%). Developed by Actavis Inc. (now part of Teva), it is a generic version of Galderma's Epiduo Forte. Adapalene is a naphthoic acid derivative with retinoid-like activity that binds to specific retinoic acid nuclear receptors (RAR-beta and RAR-gamma) to modulate cellular differentiation, keratinization, and inflammatory processes. Benzoyl peroxide is an oxidizing agent with bactericidal activity against *Cutibacterium acnes* (formerly *Propionibacterium acnes*) and possesses keratolytic and desquamative properties. This combination therapy is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adapalene + benzoyl peroxide (Actavis).